A new study reveals how Epstein-Barr virus may provoke immune cells to attack the brain, offering fresh hope for treating ...

For decades, multiple sclerosis (MS) has been defined primarily by its symptoms, rather than its underlying biology. Now, a ...

When Shanel Gamboa's legs started to tingle and go numb last fall, she attributed it to working long shifts as a neuroscience nurse with Lehigh Valley Health Network. But one morning in October, ...

Signs of multiple sclerosis may surface years before diagnosis, as patients use healthcare more often for early symptoms.

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

For years, researchers have been hopeful they could get under the hood of multiple sclerosis. The neurological condition shows up in over 2.5 million people around the world, but it doesn’t always ...

Key opinion leaders discuss the single FDA-approved option for primary progressive multiple sclerosis and emerging therapies under investigation for this MS subtype, examine the PERSEUS trial, and ...

"This agreement reflects our shared responsibility to support people living with MS," said Dimitri Gitas, Country President, Novartis Canada "Through this partnership, we're strengthening support for ...

Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.

A small study found MS patients reported improved quality of life and reduced depression after Ocrelizumab biosimilar treatment ...